Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Lung cancer, non-small cell
Stage/Subtype:  stage IIIA non-small cell lung cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 148 for your search:
Start Over
Standard or Accelerated Hypofractionated Image-Guided Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer and Poor Performance Status
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: STU 052011-093, NCI-2013-00783, NCT01459497
Comparing Photon Therapy To Proton Therapy To Treat Patients with Lung Cancer
Status: Active
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: RTOG-1308, NCI-2013-01850, NCT01993810
Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A081105, NCI-2014-01508, CALGB A081105, NCT02193282
Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E4512, NCI-2014-01507, NCT02201992
Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1302.5, NCI-2016-00374, 2014-002161-30, NCT02272413
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BR31, NCI-2015-01967, ACTRN12615000323527, IFCT1401, NCT02273375
Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D419AC00001, NCI-2015-02030, NCT02453282
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GO29527, NCI-2015-01731, NCT02486718
Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: BPI-2358-103, NCI-2015-01970, NCT02504489
AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D5164C00001, NCI-2016-00551, 2015-000662-65, NCT02511106
Panobinostat and Pemetrexed Disodium in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 08-036, NCI-2011-02483, NCT00907179
Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 25508, NCI-2010-00251, NCT01076231
Rilotumumab and Erlotinib Hydrochloride in Treating Patients With Recurrent or Progressive Advanced Non-Small Cell Lung Cancer Previously Treated With Chemotherapy
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 10-058, NCI-2011-02501, NCT01233687
Veliparib with or without Radiation Therapy, Carboplatin, and Paclitaxel in Patients with Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1206, NCI-2011-02592, CDR0000701003, CHNMC-PHII-111, PHII-111, 8811, NCT01386385
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2109, NCI-2012-00874, 2011-002578-21, NCT01449058
Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: M11VOL, NCI-2015-00776, NCT01543672
Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients with Stage II-IIIB Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2011-1058, NCI-2012-01224, NCT01629498
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CRAB CTC 11-001, NCI-2014-02260, CAR-IST-553, NCI-2013-02243, NCT01941316
A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4190C00006, NCI-2013-02416, 2015-003715-38, NCT02000947
HuMax®-TF-ADC Safety Study in Patients With Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GEN701, NCI-2014-01166, NCT02001623
Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-505, NCI-2014-00461, 9525, NCT02079740
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CEGF816X2101, NCI-2014-02651, 2013-004482-14, NCT02108964
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011X2110C, NCI-2015-01657, NCT02292550
Start Over